Cargando…
Quantum Dot-Based Screening Identifies F3 Peptide and Reveals Cell Surface Nucleolin as a Therapeutic Target for Rhabdomyosarcoma
SIMPLE SUMMARY: Rhabdomyosarcoma accounts for more than 50% of all soft tissue sarcomas in childhood and adolescence. Despite intensified multimodality treatment, prognosis is extremely poor, with an overall survival rate of approximately 20% in the advanced stage. Therefore, there is an urgent need...
Autores principales: | Dzhumashev, Dzhangar, Timpanaro, Andrea, Ali, Safa, De Micheli, Andrea J., Mamchaoui, Kamel, Cascone, Ilaria, Rössler, Jochen, Bernasconi, Michele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600270/ https://www.ncbi.nlm.nih.gov/pubmed/36291832 http://dx.doi.org/10.3390/cancers14205048 |
Ejemplares similares
-
CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models
por: Timpanaro, Andrea, et al.
Publicado: (2023) -
Surfaceome Profiling of Cell Lines and Patient-Derived Xenografts Confirm FGFR4, NCAM1, CD276, and Highlight AGRL2, JAM3, and L1CAM as Surface Targets for Rhabdomyosarcoma
por: Timpanaro, Andrea, et al.
Publicado: (2023) -
Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma
por: Alijaj, Nagjie, et al.
Publicado: (2020) -
Myogenetic Oligodeoxynucleotides as Anti-Nucleolin Aptamers Inhibit the Growth of Embryonal Rhabdomyosarcoma Cells
por: Nohira, Naoki, et al.
Publicado: (2022) -
A novel nucleolin-binding peptide for Cancer Theranostics
por: Kim, Jae-Hyun, et al.
Publicado: (2020)